Intuitive Surgical, Inc. $ISRG Stock: Eurizon Capital SGR S.p.A. Trims Stake

Eurizon Capital SGR S.p.A. cut its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.5% during the third quarter, Holdings Channel reports. The fund owned 237,653 shares of the medical equipment provider’s stock after selling 16,401 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Intuitive Surgical were worth $96,883,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Main Street Group LTD acquired a new stake in Intuitive Surgical during the 1st quarter valued at $30,000. North Point Portfolio Managers Corp OH bought a new position in Intuitive Surgical during the third quarter worth $27,000. John Boyer Inc. bought a new position in Intuitive Surgical during the third quarter worth $27,000. Compass Wealth Management LLC acquired a new position in shares of Intuitive Surgical in the third quarter valued at $29,000. Finally, Evergreen Advisors LLC acquired a new position in shares of Intuitive Surgical in the first quarter valued at $35,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Stock Down 2.1%

Shares of NASDAQ:ISRG opened at $439.89 on Friday. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88. The company’s 50 day moving average price is $416.12 and its two-hundred day moving average price is $430.38. The firm has a market cap of $152.48 billion, a PE ratio of 53.19, a PEG ratio of 3.10 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. The company had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The firm’s quarterly revenue was up 21.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.40 earnings per share. On average, research analysts expect that Intuitive Surgical, Inc. will post 9.37 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Craig H. Barratt sold 1,150 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $460.00, for a total transaction of $529,000.00. Following the completion of the sale, the director directly owned 1,150 shares in the company, valued at approximately $529,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $458.15, for a total value of $183,260.00. Following the sale, the executive vice president owned 6,236 shares of the company’s stock, valued at approximately $2,857,023.40. The trade was a 6.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 39,456 shares of company stock valued at $17,769,124 over the last ninety days. 0.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. TD Cowen reissued a “buy” rating and issued a $485.00 price objective on shares of Intuitive Surgical in a research report on Monday, October 19th. Truist Financial reduced their target price on shares of Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, July 16th. BNP Paribas Exane raised shares of Intuitive Surgical to an “outperform” rating in a report on Tuesday, July 28th. Zacks Research upgraded shares of Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 22nd. Finally, Leerink Partners set a $503.00 price target on shares of Intuitive Surgical and gave the company an “outperform” rating in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $493.54.

Intuitive Surgical Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.